Market cap of Novo Nordisk A/S [NVO] reaches 182.61B – now what?

Related

Share

Novo Nordisk A/S [NYSE: NVO] price surged by 0.31 percent to reach at $0.32. The company report on December 22, 2021 that Novo Nordisk A/S – Share repurchase programme.

Bagsværd, Denmark, 22 December 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Under the programme initiated 5 November 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 11 November 2021 to 1 February 2022.

A sum of 3327169 shares traded at recent session while its average daily volume was at 1.05M shares. Novo Nordisk A/S shares reached a high of $103.96 and dropped to a low of $100.27 until finishing in the latest session at $102.86.

The one-year NVO stock forecast points to a potential upside of 12.01. The average equity rating for NVO stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Novo Nordisk A/S [NVO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVO shares is $116.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JP Morgan have made an estimate for Novo Nordisk A/S shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 20, 2021. The new note on the price target was released on December 17, 2021, representing the official price target for Novo Nordisk A/S stock.

The Average True Range (ATR) for Novo Nordisk A/S is set at 3.05, with the Price to Sales ratio for NVO stock in the period of the last 12 months amounting to 8.91. The Price to Book ratio for the last quarter was 23.43, with the Price to Cash per share for the same quarter was set at 3.04. Price to Free Cash Flow for NVO in the course of the last twelve months was 38.85 with Quick ratio for the last quarter at 0.80.

NVO Stock Performance Analysis:

Novo Nordisk A/S [NVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.71. With this latest performance, NVO shares dropped by -6.63% in over the last four-week period, additionally plugging by 18.86% over the last 6 months – not to mention a rise of 46.75% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVO stock in for the last two-week period is set at 37.76, with the RSI for the last a single of trading hit 32.52, and the three-weeks RSI is set at 41.21 for Novo Nordisk A/S [NVO]. The present Moving Average for the last 50 days of trading for this stock 110.69, while it was recorded at 106.47 for the last single week of trading, and 93.82 for the last 200 days.

Insight into Novo Nordisk A/S Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Novo Nordisk A/S [NVO] shares currently have an operating margin of +42.63 and a Gross Margin at +81.80. Novo Nordisk A/S’s Net Margin is presently recorded at +33.19.

Return on Total Capital for NVO is now 79.74, given the latest momentum, and Return on Invested Capital for the company is 66.45. Return on Equity for this stock inclined to 69.70, with Return on Assets sitting at 31.15. When it comes to the capital structure of this company, Novo Nordisk A/S [NVO] has a Total Debt to Total Equity ratio set at 16.35. Additionally, NVO Total Debt to Total Capital is recorded at 14.06, with Total Debt to Total Assets ending up at 7.15. Long-Term Debt to Equity for the company is recorded at 4.57, with the Long-Term Debt to Total Capital now at 3.93.

Reflecting on the efficiency of the workforce at the company, Novo Nordisk A/S [NVO] managed to generate an average of $929,727 per employee. Receivables Turnover for the company is 4.72 with a Total Asset Turnover recorded at a value of 0.94.Novo Nordisk A/S’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.

NVO Stock EPS

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novo Nordisk A/S go to 12.10%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Novo Nordisk A/S [NVO] Insider Position Details

There are presently around $13,598 million, or 7.80% of NVO stock, in the hands of institutional investors. The top three institutional holders of NVO stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 21,640,671, which is approximately -10.506% of the company’s market cap and around 26.40% of the total institutional ownership; FISHER ASSET MANAGEMENT, LLC, holding 16,175,539 shares of the stock with an approximate value of $1.66 billion in NVO stocks shares; and BANK OF AMERICA CORP /DE/, currently with $765.09 million in NVO stock with ownership of nearly 2.149% of the company’s market capitalization.

Positions in Novo Nordisk A/S stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 378 institutional holders increased their position in Novo Nordisk A/S [NYSE:NVO] by around 6,984,915 shares. Additionally, 260 investors decreased positions by around 6,928,917 shares, while 187 investors held positions by with 118,700,446 shares. The mentioned changes placed institutional holdings at 132,614,278 shares, according to the latest SEC report filing. NVO stock had 104 new institutional investments in for a total of 1,374,339 shares, while 30 institutional investors sold positions of 633,837 shares during the same period.